Anthem Blue Cross Blue Shield Ohio denied my sister's prior authorization for axicabtagene ciloleucel (Yescarta) CAR-T cell therapy for relapsed refractory diffuse large B-cell lymphoma as "investigational or experimental" despite FDA approval on this exact indication since 2017, on the theory that CAR-T therapy is not "medical necessity" for her specific clinical presentation because she had not yet completed a third-line chemotherapy trial (which her oncologist at James Cancer Hospital at Ohio State documented as clinically inappropriate given her failed responses to R-CHOP and R-ICE and her disease progression on imaging), and my question is how the ERISA urgent-appeal process under 29 CFR 2560.503-1(f)(2)(i) works when the plan's medical director has denied urgent-appeal characterization despite the treating oncologist's written certification that a 72-hour decision is required because of disease progression risk, how the Ohio Department of Insurance external review through the state IRO process under RC 3922 interacts with the ERISA appeal path, what a properly built medical necessity file looks like when the underlying issue is the plan's misapplication of an "investigational" exclusion to an FDA-approved therapy, and whether there is a specialty-pharmacy versus medical-benefit routing dispute embedded in the denial (Anthem's denial letter references "specialty pharmacy formulary" language that does not appear to apply to CAR-T which is delivered through the medical benefit rather than the pharmacy benefit). the treatment center has a 21-day window to schedule her leukapheresis before the disease progression makes the CAR-T pathway unavailable. asking with the second denial letter on my kitchen counter and the treating oncology team drafting the letter of medical necessity for the external review filing.
my sister is 39 years old, a licensed physical therapist in Columbus, Ohio with two young kids ages 4 and 7, and she was diagnosed in September 2025 with diffuse large B-cell lymphoma (DLBCL), stage...